hotspot -WSS

hotspot

author：fashion 2025-10-01 00:00:12 - browse：2226

An army of wooden figures under blue and pink lighting — biotech coverage from STAT — Adobe

In an abrupt change of course from plans earlier in the month, at-home test maker Cue Health is laying off all of its employees and shutting down as of Friday, May 24.

The company, which grew to prominence during the Covid-19 pandemic as the maker of one of the only molecular at-home tests for the virus, has been teetering on the edge of insolvency for months. The shutdown, first reported by the San Diego Union-Tribune, comes just over a week after the FDA warned consumers not to use Cue’s only FDA-authorized product, a Covid-19 test kit.

Cue had previously notified 49% of its workers on May 1 that they would be laid off from the company, effective July 1. But in a WARN notice filed with California state regulators on May 20, chief human resources officer Allison Blackwell said that due to the “fluid nature of this situation,” all U.S. employees who had not already received notice of termination would be receiving one. All employees will receive their last paychecks on May 24, the notice said.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Hundreds died while taking an arthritis drug, but nobody alerted patients

WSS

Vivek Ramaswamy made waves in the debate, much as in biotech

Listen: Vivek Ramaswamy's star turn & leaky drug data

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Overprescribed: High cost isn't America's only drug problem

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

Trump to be booked at notorious Fulton County Jail at center of DOJ probe

leisure time

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

hotspot

Trump demands the U.S. pay no more for drugs than other countries … again

CDC says it’s too soon to assess risk posed by Covid subvariant

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Scientific mystery highlights the blind spots in genomics databases

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Drug companies' payments and gifts affect physicians' prescribing

23andMe had bad news about my health. I wish a person had delivered it

Trial using CRISPR to edit HIV out of cells disappoints

Activists slam private health insurers over coverage restrictions

Gut bacteria may contribute to kidney autoimmunity, study finds

explore

People with mental disorders often marry others with same

How the first Native Hawaiian psychiatrist helped diversify medicine

DeSantis wants to import drugs. Biden’s FDA blasted his plan

How the drug

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

Scientists uncover potential path to treating deadly childhood tumor

focus

focus

hotspot

knowledge